Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.7675
-0.0363-4.52%
Volume:941.97K
Turnover:740.58K
Market Cap:24.03M
PE:-0.24
High:0.8330
Open:0.8000
Low:0.7510
Close:0.8038
52wk High:5.25
52wk Low:0.7365
Shares:31.31M
Float Shares:26.89M
Volume Ratio:0.75
T/O Rate:3.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.21
PE(LYR):-0.13

Loading ...

BioXcel Therapeutics Amends Oaktree-Led Credit Agreement, Extends Deadline for Refinancing Deal to Aug. 28

Reuters
·
Yesterday

BioXcel Therapeutics - Required to Enter Definitive Agreements by August 28, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

BioXcel Therapeutics - Enters Thirteenth Amendment to Credit Agreement on August 21, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

BioXcel Therapeutics Director Susan E. Atkins Files Initial Beneficial Ownership Statement

Reuters
·
Aug 15

BioXcel Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

BioXcel Therapeutics Q2 Net Loss Narrows to USD 27.4 Million; Revenue Rises 51.67% to USD 182,000

Reuters
·
Aug 14

BioXcel Amends Oaktree-Led Credit Agreement, Cuts Minimum Liquidity Covenant to $3 Million

Reuters
·
Aug 11

BioXcel Therapeutics - Required to Enter Agreements by August 21, 2026, to Repay Obligations or Pursue Alternative Capital Solutions - SEC Filing

THOMSON REUTERS
·
Aug 11

BioXcel Therapeutics - Enters Twelfth Amendment to Credit Agreement on August 10, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 11

BioXcel Therapeutics - Lenders Reduce Minimum Liquidity Covenant to $3 Mln from $6.25 Mln - SEC Filing

THOMSON REUTERS
·
Aug 11

BioXcel Therapeutics Inc Expected to Post a Loss of 51 Cents a Share - Earnings Preview

Reuters
·
Aug 07

BioXcel Therapeutics Amends Oaktree-Led Credit Agreement, Defers Loan Payment to Aug. 31

Reuters
·
Aug 03

BioXcel Therapeutics - Lenders Defer Principal Payment to August 31, 2026; $9.02 Mln Plus Accrued Interest Due - SEC Filing

THOMSON REUTERS
·
Aug 03

BioXcel Therapeutics - Company Required to Enter Definitive Agreements by August 10, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 03

Bioxcel Therapeutics Forms Strategic Committee to Weigh Restructuring, Bankruptcy Options Under Oaktree Loan Amendment

Reuters
·
Jul 06

BioXcel Therapeutics posts new Phase 3 SERENITY At-Home data for BXCL501 in agitation linked to bipolar disorder, schizophrenia

Reuters
·
May 28

BioXcel Therapeutics Presents New Data From Serenity at-Home Phase 3 Trial for Agitation Associated With Bipolar Disorders or Schizophrenia at 2026 Ascp Annual Meeting

THOMSON REUTERS
·
May 28

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BioXcel net loss widens to $12.69 million in Q1 FY26

Reuters
·
May 15

BioXcel Therapeutics Inc - FDA Accepts Igalmi at-Home Snda; Pdufa Date Set for Nov 14, 2026

THOMSON REUTERS
·
May 15